Continued support for Ministry of Health's policies regarding switching patients to biosimilar medicines from biologics
|
- Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
Expansion of reimbursement criteria by the Government of British Columbia for biosimilar products.
|
- Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
Policy and timing in respect of listing of sole-source and other generic drugs on the PharmaCare formulary where the price offered is higher than the Province's desired price. BC's position in respect of administration of pan-Canadian Pharmaceutical Association arrangements with the CGPA regarding generic drugs. Curtailing use of coupon cards for pharmaceutical products. Development of a regulatory pathway for biosimiars. Implementation of commitments made by British Columbia pursuant to its involvement with the pan-Canadian Pharmaceutical Alliance. Promoting greater utilization of generic prescription medicines. BC's position in respect of the National Pharmacare initiative. Accelerating time for listing of generic drugs after submission.
|
- Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation
- Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|